MONEPANTEL PHARMACO-THERAPEUTIC EVALUATION IN CATTLE: PATTERN OF EFFICACY AGAINST MULTIDRUG RESISTANT NEMATODES

Canton, Candela*; Canton, Lucila; Lifschitz, Adrian; Domínguez, María Paula; Torres, Juan; Lanusse, Carlos; Alvarez, Luis; Ceballos, Laura; Ballent, Mariana

Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN), UNCPBA-CICPBA-CONICET, Facultad de Ciencias Veterinarias, Campus Universitario, (7000) Tandil, Argentina

*Corresponding author: Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN), CONICET, Facultad de Ciencias Veterinarias, UNCPBA. Campus Universitario, 7000 Tandil, Argentina. Tel/Fax: 54-249-4385850. E-mail address: ccanton@vet.unicen.edu.ar
ABSTRACT

The goal of the current work was to perform an integrated evaluation of monepantel (MNP) pharmacokinetics (PK) and pharmacodynamics, measured as anthelmintic efficacy, after its oral administration to calves naturally infected with GI nematodes resistant to ivermectin (IVM) and ricobendazole (RBZ) on three commercial farms. On each farm, forty-five calves were randomly allocated into three groups (n= 15): MNP oral administration (2.5 mg/kg); IVM subcutaneous (SC) administration (0.2 mg/kg); and RBZ SC administration (3.75 mg/kg). Eight animals from the MNP treated group (Farm 1) were selected to perform the PK study. Drug concentrations were measured by HPLC. The efficacy was determined by the faecal egg count reduction test (FECRT). MNP and MNP-sulphone (MNPSO₂) were the main analytes recovered in plasma. MNPSO₂ systemic exposure was markedly higher compared to that obtained for MNP. Higher Cmax and AUC values were obtained for the active MNPSO₂ metabolite (96.8 ± 29.7ng/mL and 9220 ± 1720ng.h/mL) compared to MNP (21.5 ± 4.62ng/mL and 1709 ± 651ng.h/mL). The MNPSO₂ AUC value was 6-fold higher compared to the parent drug. Efficacies of 99% (Farm 1), 96% (Farm 2) and 98% (Farm 3) demonstrated the high activity of MNP (P< 0.05) against GI nematodes resistant to IVM (reductions between 27 and 68%) and RBZ (overall efficacy of 75% on Farm 3). While IVM failed to control Haemonchus spp. and Cooperia spp., and RBZ failed to control Cooperia spp. and Ostertagia spp., MNP achieved 100% efficacy against Haemonchus spp., Cooperia spp. and Ostertagia spp. However, a low efficacy of MNP against Oesophagostomum spp. (efficacies ranging from 22 to 74%) was observed. In conclusion, oral treatment with MNP should be considered for dealing with IVM and benzimidazole resistant nematode parasites in cattle.
The work described here reports for the first time an integrated assessment of MNP pharmaco-therapeutic features and highlights the need to be considered as a highly valuable tool to manage nematode resistant to other chemical families.

**Keywords:** Monepantel - Cattle - Resistant nematodes - Pharmaco-parasitological assessment
1. INTRODUCTION

Considering the increasing prevalence and worldwide dissemination of gastrointestinal (GI) nematodes resistant to most of the available anthelmintic families, drug resistance is considered one of the main sanitary problems in extensive cattle production systems today (Kaplan, 2020). During the last decades, chemical control has been mainly based on the use of only three anthelmintic chemical families: macrocyclic lactones (ML), benzimidazoles (BZD) and imidazothiazoles. Furthermore, since GI parasitism has a high impact on animal production, these anthelmintic drugs have been intensively used at short intervals in different cattle production grazing systems worldwide. This heavy reliance on anthelmintics to control parasitism and the limited implementation of refugia-based sustainable control programmes have led to the development of resistance to all the available chemical groups. Unfortunately, resistance is becoming a worldwide serious problem, particularly in countries such as New Zealand (Waghorn et al., 2006), Brazil (Ramos et al., 2016), Australia (Rendell, 2010), Uruguay (Mederos et al., 2019), United States (Kaplan, 2020) and Argentina (Cristel et al., 2017) among many others. Despite the complex current situation regarding the widespread development of anthelmintic resistance, dependence on chemically-based control continues to be high since it is still the most practical option for parasite control on commercial beef cattle farms.

The increasing levels of resistance to all traditional drug classes and the still high dependence on anthelmintics for controlling parasitic nematodes, have encouraged the introduction of new molecules with different modes of action into the veterinary
The compound monepantel (MNP) is a compound of a new family of anthelmintics, the amino-acetonitrile derivatives, developed to treat ruminants infected with GI nematodes (Kaminsky et al., 2008). Its mode of action is different from the other available anthelmintic families since it acts as a positive allosteric modulator of the nematode specific acetylcholine receptor MPTL-1 (Rufener et al., 2009, 2010). MNP binding to this receptor results in a constant uncontrolled flux of ions and finally in a depolarization of muscle cells leading to nematode paralysis (Epe and Kaminsky, 2013). The cellular target of MNP, the MPTL-1 receptor, is so far only present in nematodes, which might explain the excellent tolerability of MNP in mammals and its high efficacy against multidrug-resistant parasites to other anthelmintic classes in sheep and cattle (Baker et al., 2012; King et al., 2015). The first formulation of MNP, launched in 2009, was licensed for exclusive use in sheep, and some years later was also introduced in a limited number of countries as an oral formulation for use in cattle (King et al., 2015). The disposition kinetics and distribution to target tissues of MNP have been previously described in sheep (Lifschitz et al., 2014), and some data on plasma profiles in dairy cows have been also reported (Ballent et al., 2017). However, until now there have been no published reports regarding the relationship between MNP pharmacokinetics and its efficacy against resistant GI nematodes in beef cattle.

The goal of the work described here was to perform an integrated evaluation of MNP pharmacokinetics (PK) and pharmacodynamics (PD), assessed as anthelmintic efficacy, after its oral administration to calves naturally infected with GI nematodes resistant to ivermectin (IVM) and ricobendazole (RBZ) on three commercial farms.
2. MATERIAL AND METHODS

2.1. Field Trial

This study was conducted on three cattle commercial farms located in the Humid Pampean Region, Argentina. All farms (Farms 1, 2 and 3) had a grazing system of meat production representative of Argentina bovine production. The resistance status of the nematode population characteristic of each farm was previously determined by the faecal egg count reduction test (FECRT) (Canton et al., 2019). In this way, the study included two farms with a predominance of IVM and RBZ-resistant nematode population (Farms 1 and 3) and one farm with only an IVM-resistant nematode population (Farm 2).

2.2. Animals

All the farms involved in the trial raise calves acquired from other producers. The herd on each farm from which the animals were selected were treated with levamisole prior to the study to remove their worm infections. It is important to point out that resistance to levamisole has not been reported in this region of Argentina (Cristel et al., 2017). They had then grazed on the study farms for at least two months prior to the study, which ensured that their parasite burden was native from each Farm. All the animals had free access to water.

On day -1, 60 (Farms 1 and 3) or 80 (Farm 2) male Aberdeen Angus calves, aged 9–11 months old, naturally infected with GI nematodes resistant to IVM and RBZ (Farms 1 and 3)
or resistant to IVM (Farm 2), were checked for worm egg per gram (EPG) counts, ear-tagged, and the individual body weights were recorded. The animals for inclusion in the trial were then selected based on the EPG counts. Forty-five (45) animals on each farm, with at least 100 EPG on day -1, were selected for inclusion in the study. Experimental animals had an average of 508 EPG counts ranging from 100 to 2440 on Farm 1, 274 EPG counts ranging from 100 to 660 on Farm 2, and 450 EPG counts ranging from 140 to 1440 on Farm 3.

Animal procedures and management protocols were approved by the Ethics Committee (act 11/2020) of the Facultad de Cs. Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Tandil, Argentina.

2.3. Treatments

On each farm (1, 2 and 3), all parasitized animals (n=45) were ranked according to EPG counts, and then randomly assigned into three groups of 15 animals each: MNP: animals were treated with MNP (Zolvix®, 2.5% solution, Elanco, Argentina) by the oral route at a dose of 2.5 mg/kg; IVM: animals were treated with IVM (Ivomec®, 1% solution, Boehringer Ingelheim, Argentina) by the subcutaneous (SC) route at 0.2 mg/kg and RBZ: animals were treated with RBZ (Bayverm PI®, 15% solution, Bayer, Argentina) by the SC route at 3.75 mg/kg. The mean EPG were similar (P>0.05) across all groups on each farm at the beginning of the trial.

2.4. Monepantel PK trial
The PK trial was carried out on Farm 1. Eight randomly selected animals from the MNP treated group were used in the PK trial. Blood samples (10 mL) were taken from the jugular vein in heparinised Vacutainer® tubes (Becton Dickinson, NJ, USA) before treatment and at 2, 4, 6, 8 and 10 h and 1, 2, 3, 5, 7 and 9 days post-treatment. Plasma was separated by centrifugation at 3000 g for 15 min, placed into plastic tubes and frozen at -20°C until analysis by High Performance Liquid Chromatography (HPLC).

2.5. Anthelmintic efficacy trial: faecal egg count reduction test and coprocultures

Faecal samples were individually collected directly from the rectum of each calf during pre-treatment (day -1) and again on day 15 post-treatment. A modified McMaster technique with a sensitivity of 10 EPG (Roberts and O’sullivan, 1950) was used to analyse the faecal samples and estimate EPG counts. Additionally, 10 g of faeces (obtained from an individual animal and/or from a pool of each experimental group) was used to prepare coprocultures on each sampling day. The nematode genera and species were identified through the third-stage larvae recovered from these coprocultures (MAFF, 1986). Third stage larvae (L₃) were collected by the Baermann technique and approximately 100 L₃ were differentiated from each sample. Thus, the relative participation of each genus per experimental group was determined.

The anthelmintic efficacy of the different treatments was assessed by the faecal egg count reduction test (FECRT), calculated according to the following formula (McKenna, 1990):

\[
\text{FECRT (\%)} = 100 \left(1 - \frac{T2}{T1}\right)
\]
where T2 is the arithmetic mean EPG count in each treated group at 15 days post-treatment, and T1 is the arithmetic mean EPG count in each treated group on day -1. The 95% confidence intervals were calculated as reported by Coles et al. (1992). Besides, efficacy against different genera was calculated by dividing the mean faecal egg count of each treatment group at day -1 and 15 post-treatment, by the proportion of L3 of each genus in the associated coproculture (McKenna, 1990).

2.6. Analytical procedures

MNP and its metabolite, MNP-sulphone (MNPSO₂), concentrations were determined in plasma by HPLC with UV detection. Briefly, MNP/MNPSO₂ were extracted from plasma (0.5 mL) by the addition of 1 mL of acetonitrile. The preparation was mixed with a high-speed shaker (Multi Tube Vortexer, VWR Scientific Products, West Chester, PA) for 15 minutes at room temperature to allow phase separation. The solvent-sample mixture was centrifuged at 2000 g for 10 min at 4 °C and the supernatant was manually transferred into a clean tube. This volume was evaporated to dryness under a gentle stream of dry nitrogen at 56 °C in a water bath. Finally, the dried residue was reconstituted with 250 µL of mobile phase (acetonitrile:methanol:water 60:8:32, v/v/v) and 200 µL of this solution was injected directly into the chromatography system.

MNP plasma concentration was determined by HPLC (Shimadzu 10 A-HPLC System, Kyoto, Japan) with a UV detector set at 230 nm following a method previously developed (Ballent et al., 2017; Lifschitz et al., 2014). A C₁₈ reversed-phase column (Kromasil, Eka Chemicals,
Bohus, Sweden, 5 μm, 4.6 × 250 mm) was used for separation. Elution of MNP and MNPSO$_2$ from the stationary phase was carried out at a flow rate of 0.8 mL/min (MNP) using acetonitrile/methanol/water (60:8:32, v/v/v). Under the described chromatographic conditions, the retention times (min) were established at 9.3 (MNPSO$_2$) and 12.5 (MNP). There was no interference of endogenous compounds in any of the chromatographic determinations. A calibration curve in the range between 4-400 ng/mL was prepared for both molecules. The plasma calibration curve had a correlation coefficient ≥ 0.998. Mean absolute recovery percentages for concentrations ranging between 4 and 400 ng/mL (n= 6) were 74.9% (MNP) and 74.1% (MNPSO$_2$) with coefficients of variation (CV) of 14.1% and 15.7, respectively. Accuracy (expressed as the relative error) and precision (expressed as the coefficient of variation) were 10% and 5.2%, respectively. The limit of quantification (LOQ) was established at 4 ng/mL for MNP and MNPSO$_2$, which is the lowest concentration measured with a recovery higher than 70% and a CV < 20%. In all cases, concentration values below the LOQ were not considered for the kinetic analysis of experimental data.

2.7. Pharmacokinetic analysis of the data

The concentration vs. time curves for MNP and MNPSO$_2$ in plasma for each animal after the different treatments was fitted with the PK Solution 2.0 software (Summit Research Service, CO, USA). The peak concentration (Cmax) and time to peak concentration (Tmax) were recorded directly from the measured concentration data. The elimination half-life (T$_{1/2}$el) and absorption half-life (T$_{1/2}$abs) were calculated as ln2/$\lambda$$_{el}$ and ln 2/$k$$_{abs}$, respectively, where $\lambda$$_{el}$ is the elimination rate constant and $k$$_{abs}$ represents the first-order absorption rate constant.
The rates were calculated by performing regression analysis using data points belonging to the terminal or absorption phase concentration-time plot. The area under the plasma concentration-time curve from zero up to the quantification limit (AUC_0-LOQ) was calculated using the trapezoidal rule (Gibaldi and Perrier, 1982) and further extrapolated to infinity (AUC_0-\infty) by dividing the last experimental concentration by the terminal elimination rate constant (\(\lambda_{el}\)). Statistical moment theory was applied to calculate the mean residence time (MRT) according to Perrier and Mayersohn (1982). PK analysis of the experimental data was performed using a non-compartmental model method.

2.8. Statistical analysis of the data

The PK parameters and concentration data are reported as arithmetic mean ± Standard Deviation (SD). PK parameters for MNP and MNPSO_2 were statistically compared using Student t-test. Faecal egg counts (reported as arithmetic mean ± SD) were compared by non-parametric Kruskal–Wallis test. A value of P<0.05 was considered statistically significant. The statistical analysis was performed using the Instat 3.0 software (Graph Pad Software, CA, USA).

3. RESULTS

MNP and MNPSO_2 were the main analytes recovered in plasma after oral administration of MNP to cattle. The mean (± SD) plasma concentrations profiles of MNP and its MNPSO_2 metabolite are shown in Fig. 1. MNPSO_2 systemic exposure was markedly higher compared to that obtained for MNP. It accounted for >80 % of the total amount of the analytes recovered in plasma. While low concentrations of MNP were measured in plasma only up to
120 h (5 days) post-administration, the persistence of the sulphone metabolite was longer in the bloodstream, being recovered up to 216 h (9 days). These differences were reflected in the values estimated for the main PK parameters. Table 1 summarizes the plasma PK parameters for MNP and MNPSO obtained after the oral administration of MNP to cattle. Higher Cmax and greater AUC values were obtained in plasma for MNPSO compared to MNP. In fact, the AUC value for MNPSO were 6-fold higher compared to those reported for the parent drug (MNPSO/MNP AUC ratio= 5.99 ± 2.08).

Table 2 shows the overall faecal egg counts (arithmetic mean) and reduction percentages of faecal egg counts (FECR) (undifferentiated) with its 95% lower and upper confidence intervals obtained for all experimental groups on Farms 1, 2 and 3. The results of the FECRT with 99%, 96% and 98% of reduction for MNP on Farms 1, 2, and 3, respectively, demonstrated the high efficacy of this amino-acetonitrile derivative against GI nematodes resistant to IVM and RBZ in cattle. In fact, the low efficacies obtained for IVM (43%, 68% and 27% of reduction) confirm the presence of resistant parasites to this anthelmintic. On the other hand, the overall efficacy for RBZ on Farm 2 was 98%, demonstrating that this farm was the only one included in the study with a predominance of a RBZ-susceptible nematode population. Although the total efficacy for RBZ on Farm 1 was 94%, the 95% lower confidence interval for this anthelmintic was less than 90%, indicating an initial level of resistance. Finally, a higher level of resistance for RBZ was reported on Farm 3, where an overall reduction of 75% confirms the presence of resistant GI nematodes. In this context, whilst on Farms 1 and 2 significant (P< 0.05) differences were only observed between EPG
counts post-IVM and MNP treatments, on Farm 3, the EPG counts after MNP were significantly (P< 0.05) lower than the egg counts after both IVM and RBZ.

The anthelmintic efficacies against *Cooperia* spp., *Haemonchus* spp., *Ostertagia* spp. and *Oesophagostomum* spp. for the different treatments on Farms 1, 2 and 3, are shown in Table 3. On Farms 1 and 3 IVM failed to control *Haemonchus* spp. and *Cooperia* spp., showing efficacies ranging from 0% to 80%. In the case of Farm 2, only IVM-resistant *Cooperia* spp. was present, being the others GI nematode genera susceptible to RBZ. The BZD treatment failed to control *Cooperia* spp. and *Ostertagia* spp. on Farms 1 and 3 (FECR below 90% for both nematode genera). In contrast, MNP was the only treatment that achieved 100% efficacy against *Cooperia* spp., *Haemonchus* spp. and *Ostertagia* spp., including against resistant parasites (99% against *Ostertagia* spp. on Farm 3). However, MNP failed to control *Oesophagostomum* spp., showing low efficacies of 74%, 22% and 64% against this genus on Farms 1, 2, and 3, respectively.

Finally, no adverse events were observed in any of the cattle treated with MNP.

4. DISCUSSION

Since GI parasitism negatively affects weight gain in grazing animals (Charlier et al., 2014a), parasite control is necessary to ensure adequate production levels on beef cattle farms. Alternative nematode control strategies, such as grazing management, host genetic resistance and helminth vaccines, are now being developed for further reduce reliance on chemically-based parasite control (Charlier et al., 2014b). However, dependence on
anthelmintics continues to be high, since it is still being the most practical tool for parasite control on large scale commercial beef cattle farms. Due to the enormous difficulties involved in the development of novel anthelmintic molecules, such as the lastly introduced amino-acetonitrile derivative MNP, it is essential to understand its pharmacological behaviour to optimize its use in cattle under natural field conditions. The work described here reports for the first time an integrated assessment of MNP pharmacokinetics and pharmacodynamics (measured as anthelmintic efficacy), in cattle naturally infected with GI nematodes resistant to IVM and RBZ on a field trial performed on three different commercial farms.

The MNP plasma disposition kinetics has not been described in beef cattle. However, in line with previous PK studies in sheep (Karadzovska et al., 2009; Lifschitz et al., 2014) and dairy cows (Ballent et al., 2017), a rapid decline in the plasma profiles of the parent drug and the recovery of the MNPSO$_2$ metabolite as the main analyte detected in the bloodstream, were observed in beef calves in the current trial. The metabolic conversion of MNP into MNPSO$_2$ also involves the production of an intermediate sulphoxide derivative (Karadzovska et al., 2009), which is rapidly and almost completely converted into MNPSO$_2$, being undetectable in plasma of MNP treated animals. In fact, the Cmax of the sulphone metabolite was four times higher than the corresponding parent concentration (21.5 vs 96.8 ng/mL for MNP and MNPSO$_2$, respectively). Moreover, when MNP reached the Cmax (at 8 h post-oral treatment), the MNPSO$_2$ metabolite was already about twice as high. Since MNPSO$_2$ is an active metabolite against nematodes (Karadzovska et al., 2009), its high plasma and GI
exposure greatly contribute to the overall MNP nematodicial efficacy. In fact, the ratio of the total plasma AUC of MNPSO₂ over the total AUC of MNP in both species, exhibited higher systemic exposure for MNPSO₂ compared to the parent drug after the oral administration of MNP. However, interspecies differences in MNPSO₂ systemic availability were observed between cattle and sheep. While Lifschitz et al. (2014) reported a MNPSO₂/MNP AUC ratio of about 12 in sheep, a 50% lower value is described for that ratio after oral administration of MNP in cattle (Table 1). This finding may be explained by the different patterns of MNP liver metabolism (S-oxidation) between sheep and cattle. The rate of MNP conversion into MNPSO₂ was five-fold higher in sheep compared to cattle (Ballent et al., 2016). While in sheep, the formation of the sulphone metabolite is based on the enzymatic activity of both flavin-monoxygenase (FMO) and cytochrome P-450 (CYP), in cattle MNP is converted into MNPSO₂ only in a CYP-mediated metabolic reaction (Ballent et al., 2016). These interspecies differences do not necessarily imply lower exposure of worms to the active drug. Moreover, considering MNP anthelmintic activity may be mainly based on a considerable drug/metabolite accumulation in the GI tissues and fluid contents during the first 2 to 3 days post-treatment, the different patterns of MNP liver metabolism between sheep and cattle should not affect its efficacy against GI nematodes (Lifschitz et al. 2014).

The results of the current PK assessment in cattle and those reported in sheep by Lifschitz et al. (2014) on the characterization of MNP accumulation in target tissues, give strong pharmacological support to the anthelmintic efficacy findings. The increasing worldwide prevalence of GI nematodes resistant to most of the traditional anthelmintic groups such as
ML and BZD, therapeutic failures associated with anthelmintic resistance has enormous economic importance of global significance, particularly in countries where weather and production conditions contribute to a high incidence of parasitism. For instance, resistance to IVM was diagnosed in 93% of the farms tested in Argentina, while resistance to RBZ was diagnosed in 28% of the farms included in a nation-wide survey (Cristel et al., 2017). The main resistant genera were *Cooperia* spp. and *Haemonchus* spp. to IVM, and *Ostertagia* spp. and *Cooperia* spp. to RBZ (Cristel et al., 2017). Therefore, the efficacy of MNP was evaluated in scenarios where the nematode population was representative of the real situation on most commercial cattle farms. In this context, the efficacy results showed 99%, 96% and 98% of reduction for MNP on Farms 1, 2 and 3, respectively. These results demonstrated the high efficacy of MNP against resistant GI nematodes in cattle. Only limited information is available on MNP efficacy against GI nematodes in cattle (King et al., 2015). In that particular trial, MNP was administered in a combined formulation with abamectin. However, the reported efficacy results are consistent with those observed in our current trial with efficacies measured by FECR ranging from 98.3 to 99.9%. Similarly, the efficacy results observed in the present work are consistent with several studies in sheep (Bustamante et al., 2009; Hosking et al., 2009; Kaminsky et al., 2009; Sager et al., 2009). Bustamante et al. (2009) also evaluated MNP efficacy against IVM resistant nematode parasites. The low IVM efficacies obtained in the current work (43%, 68% and 27% of reduction on Farms 1, 2 and 3), confirm the presence of resistant nematode populations to this ML anthelmintic. Additionally, MNP was the only treatment that achieved >95% both in the overall efficacy and in the 95% lower confidence interval.
It should be considered that GI parasitism in cattle always involves different parasite genera. In this sense, while on Farms 1 and 3 IVM failed to control *Cooperia* spp. and *Haemonchus* spp., on Farm 2 *Cooperia* spp. was the only genus resistant to IVM. *Cooperia* spp. is commonly present in the cases of IVM resistance in cattle. In fact, resistant *Cooperia* spp. was recovered in 100% of the farms where resistance to IVM were present in a survey carried out in Argentina in 2017 (Cristel et al. 2017). *Cooperia* spp. is one of the genera in which resistance to IVM is more frequent not only because it is a “dose-limiting” parasite for IVM (Benz et al., 1989), but also because routine IVM treatments are administered in the absence of any significant larval population in refugia (Sauermann and Leathwick 2018). However, similarly to our findings, some studies have also reported both *Cooperia* spp. and *Haemonchus* spp. resistant to IVM (Anziani et al., 2004; Ramos et al., 2016; Canton et al., 2018). Although RBZ achieved higher overall efficacies than IVM, the BZD treatment did not show effective control against all the GI nematodes present on Farms 1 and 3. Indeed, on these farms, RBZ failed to control *Cooperia* spp. and *Ostertagia* spp. (FECR below 90% for both nematode genera). In contrast, MNP was the only treatment that achieved 100% efficacy against *Cooperia* spp., *Haemonchus* spp. and *Ostertagia* spp. Similar results were found in different studies in sheep against resistant GI nematodes. Hosking et al. (2008) and Sager et al. (2009) demonstrated high (>95%) efficacy of MNP administered orally to sheep against GI nematodes resistant to either BZ or levamisole. Furthermore, Steffan et al. (2011) and Baker et al. (2012) showed almost 100% efficacy of MNP against GI nematodes multiple
resistant to BZ, levamisole and ML. Although those studies were performed in sheep, their results and resistance scenarios were comparable with the current trial of MNP in cattle.

Efficacy of MNP against *Oesophagostomum* spp. is a particularly relevant issue due to efficacy results failing to meet an adequate reduction. The findings of the present study in cattle demonstrated that MNP failed only to control *Oesophagostomum* spp., with efficacies ranging from 22% to 74%. Similarly, it has been reported in sheep that *Oesophagostomum* was only reduced by 88% (Sager et al., 2009) and 61.9% (Bustamante et al., 2009). Furthermore, Hosking et al. (2009) also found efficacies below 90% against this nematode in sheep. In fact, the dose of 2.5 mg/kg was established as a suitable minimum dose rate (Kaminsky et al., 2009), because lower doses failed to control *Oesophagostomum* spp., which was established as the dose-limiting nematode for MNP (Hosking et al., 2010). Although a reduced sensitivity of this genus to MNP may explain its low efficacy, Lifschitz et al. (2014) suggested that a PK-related issue should contribute to this limited therapeutic response in sheep. The lower concentration of MNP achieved in the large intestine mucosa (225 ng/g) compared to that measured in the small intestine mucosa (562 ng/g in the ileum and 762 ng/g in the duodenum) may explain the efficacy levels obtained against *Oesophagostomum* spp. (Lifschitz et al., 2014), situation that could also occur in cattle. The PK/PD of MNP against GI nematodes may suggest that the high concentrations of MNP parental drug achieved in the GI contents and mucosa during 48-72 h after its oral administration are relevant to the effectiveness of this compound (Lifschitz et al., 2014).
The activity of MNP against multidrug-resistant parasites, which is based on its novel mode of action, is a highly favorable element. However, resistance to MNP has occurred on the field within less than 2 years of the product first being used in sheep and goats in New Zealand. In this first report of resistance in goats excessively treated with the amino-acetonitrile derivative, MNP was ineffective against at least two GI nematode species, *Teladorsagia circumcincta* and *Trichostrongylus colubriformis* (Scott et al., 2013). Moreover, Mederos et al. (2014) found *Haemonchus contortus* resistant to MNP on sheep farms in Uruguay. Lack of efficacy of MNP was also reported on sheep farms in the Netherlands (van den Brom et al., 2015), Brazil (Cintra et al., 2016), Australia (Sales and Love, 2016), Argentina (Illanes et al., 2018) and the United Kingdom (Hamer et al., 2018; Bartley et al., 2019).

Considering that resistance to MNP has already been reported in sheep in different countries, it is essential to understand the mechanisms of resistance to this compound. In this way, the presence of multiple separate mutations in the MPTL-1 gene in field-derived *H. contortus* and *T. circumcincta* isolates may at least partly explain MNP resistance (Bagnall et al., 2017; Turnbull et al., 2019). The reports of resistance highlight the need to learn from the use of this anthelmintic on sheep farms. It is essential to maintain the awareness on the possibility of development of resistance to MNP in cattle nematode parasites, which includes the need to follow appropriate guidelines of parasite control (Bartley et al., 2019).

Overall, there is no published reports on the simultaneous assessment of the relationship between the PK performance and the anthelmintic therapeutic response to MNP in cattle. The results of the current work determined that the oral route is a very efficient
administration route for MNP in beef cattle. This is particularly relevant when the described high systemic exposure of the anthelmintically active MNP and MNPSO₂ exposure is considered. MNP achieved effective control of GI nematodes with multiple anthelmintic resistance to ML and BZD. The widespread appearance of resistant parasites highlights the need for novel anthelmintics acting at novel target sites to be used in cattle, such as MNP. However, it is now crucial to accomplish adequate management of this novel compound to prolong its lifespan and optimize parasite control based on diagnosis and treatment strategies implemented on an individual cattle farm basis. The findings described here contribute to the knowledge on MNP pharmacology and efficacy against resistant GI nematodes in beef cattle.

ACKNOWLEDGEMENTS

This study was funded by Agencia Nacional de Promoción Científica y Técnica (ANPCyT) (PICT 2014-0683) from Argentina. The authors would like to thank the farmers for collaborating with this study.

CONFLICT OF INTEREST STATEMENT

There are no potential conflicts of interest associated with this study.
REFERENCES

Anziani, O., Suarez, V., Guglielmone, A., Warnke, O., Grande, H., Coles, G., 2004. Resistance to benzimidazole and macrocyclic lactone anthelmintics in cattle nematodes in Argentina. Vet. Parasitol. 122, 303–306.

Bagnall, N., Ruffell, A., Raza, A., Elliott, T., Lamb, J., Hunt, P., Kotze, A., 2017. Mutations in the Hco-mptl-1 gene in a field-derived monepantel-resistant isolate of Haemonchus contortus. Int. J. Parasitol. Drugs Drug Resist. 7, 236–240.

Baker, K., George, S., Stein, P., Seewald, W., Rolfe, P., Hosking, B., 2012. Efficacy of monepantel and anthelmintic combinations against multiple-resistant Haemonchus contortus in sheep, including characterisation of the nematode isolate. Vet. Parasitol. 186, 513–517.

Ballent, M., Virkel, G., Maté, L., Viviani, P., Lanusse, C., Lifschitz, A., 2016. Hepatic biotransformation pathways and ruminal metabolic stability of the novel anthelmintic monepantel in sheep and cattle. J. Vet. Pharmacol. Ther. 39, 488–496.

Ballent, M., Viviani, P., Imperiale, F., Dominguez, P., Halwachs, S., Mahnke, H., Honscha, W., Lanusse, C., Virkel, G., Lifschitz, A., 2017. Pharmacokinetic assessment of the monepantel plus oxfendazole combined administration in dairy cows. J. Vet. Pharmacol. Ther. 1–9.

Bartley, D., Hamer, K., Andrews, L., Sargison, N., Morrison, A., 2019. Multigeneric resistance to monepantel on a UK sheep farm. Vet. Parasitol.: X 1, 100003.

Benz, G., Roncalli, R., Gross, S., 1989. Use of ivermectin in cattle, sheep, goats, and swine. In: W.C. Campbell (Ed.), Ivermectin and Abamectin. Springer, Berlin, pp. 214–229.
Bustamante, M., Steffan, P., Bonino Morlán, J., Echevarria, F., Fiel, C., Cardozo, H., Castells, D., Hosking, B., 2009. The efficacy of monepantel, an amino-acetonitrile derivative, against gastrointestinal nematodes of sheep in three countries of southern Latin America. Parasitol. Res. 106, 139–144.

Canton, C., Canton, L., Domínguez, M.P., Moreno, L., Lanusse, C., Alvarex, L., Ceballos, L., 2018. Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle. Vet. Parasitol. 256, 43–49.

Canton, C., Ceballos, L., Moreno, L., Domínguez, P., Cantón, L., Buffarini, M., Lanusse, C., Alvarez, L., 2019. Anthelmintic Combinations: a Sustainable Strategy to Optimize Parasite Control on Commercial Cattle Farms?, in: Proceedings of The 27th Conference of the World Association for the Advancements of Veterinary Parasitology (W.A.A.V.P.). Madison, Wisconsin, USA, p. 118.

Charlier, J., van der Voort, M., Kenyon, F., Skuce, P., Vercruysse, J., 2014a. Chasing helminths and their economic impact on farmed ruminants. Trends in Parasitol. 30, 361–367.

Charlier, J., Morgan, E., Rinaldi, L., van Dijk, J., Demeler, J., Höglund, J., Hertzberg, H., van Ranst, B., Hendrickx, G., Vercruysse, J., Kenyon, F., 2014b. Practices to optimise gastrointestinal nematode control on sheep, goat and cattle farms in Europe using targeted (selective) treatments. The Vet. Rec. 175, 250–5.

Cintra, M., Teixeira, V., Nascimento, L., Sotomaior, C., 2016. Lack of efficacy of monepantel against *Trichostrongylus colubriformis* in sheep in Brazil. Vet. Parasitol. 216, 4-6.

Coles, G.C., Bauer, C., Borgsteede, F., Geerts, S., Klei, T., Taylor, M., 1992. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) methods for the detection
of anthelmintic resistance in nematodes of veterinary importance. Vet. Parasitol. 44, 35–44.

Cristel, S., Fiel, C., Anziani, O., Descarga, C., Cetrá, B., Romero, J., Fernández, S., Entrocasso, C., Lloberas, M., Medus, D., Steffan, P., 2017. Anthelmintic resistance in grazing beef cattle in central and northeastern areas of Argentina — An update. Vet. Parasitol.: Reg. Stud. Reports 9, 25–28.

Epe, C., Kaminsky, R., 2013. New advancement in anthelmintic drugs in veterinary medicine. Trends in Parasitol. 29, 129–134.

Gibaldi, M., Perrier, D., 1982. Pharmacokinetics. 2nd ed, Revised and Expanded. Marcel Dekker, New York, USA.

Hamer, K., Bartley, D., Jennings, A., Morrison, A., Sargison, N., 2018. Lack of efficacy of monepantel against trichostrongyle nematodes in a UK sheep flock. Vet. Parasitol. 257, 48–53.

Hosking, B., Dobson, D., Stein, P., Kaminsky, R., Bapst, B., Mosimann, D., Mason, P., Seewald, W., Strehlau, G., Sager, H., 2009. Dose confirmation studies for monepantel, an amino-acetonitrile derivative, against fourth stage gastro-intestinal nematode larvae infecting sheep. Vet. Parasitol. 160, 251–257.

Hosking, B., Kaminsky, R., Sager, H., Rolfe, P., Seewald, W., 2010. A pooled analysis of the efficacy of monepantel, an amino-acetonitrile derivative against gastrointestinal nematodes of sheep. Parasitol. Res. 106, 529–532.
Hosking, B., Stein, P., Mosimann, D., Seewald, W., Strehlau, G., Kaminsky, R., 2008. Dose determination studies for monepantel, an amino-acetonitrile derivative, against fourth stage gastro-intestinal nematode larvae infecting sheep. Vet. Parasitol. 157, 72–80.

Illanes, F., Romero, J., Niño Uribe, A., Pruzzo, C., 2018. Primer informe de resistencia antihelmíntica a monepantel en ovinos de la provincia de Corrientes, Argentina. Vet. Argentina 32, 1–7.

Kaminsky, R., Ducray, P., Jung, M., Clover, R., Rufener, L., Bouvier, J., Weber, S., Wenger, A., Wieland-Berghausen, S., Goebel, T., Gauvry, N., Pautrat, F., Skripsiy, T., Froelich, O., Komoin-Oka, C., Westlund, B., Sluder, A., Mäser, P., 2008. A new class of anthelmimtics effective against drug-resistant nematodes. Nature 452, 176–180.

Kaminsky, R., Mosimann, D., Sager, H., Stein, P., Hosking, B., 2009. Determination of the effective dose rate for monepantel (AAD 1566) against adult gastro-intestinal nematodes in sheep. Int. J. Parasitol. 39, 443–446.

Kaplan, R., 2020. Biology, Epidemiology, Diagnosis, and Management of Anthelmintic Resistance in Gastrointestinal Nematodes of Livestock. Vet. Clin. North Am. - Food Anim. Pract. 36, 17-30.

Karadzovska, D., Seewald, W., Browning, A., Smal, M., Bouvier, J., Giraudel, J., 2009. Pharmacokinetics of monepantel and its sulfone metabolite, monepantel sulfone, after intravenous and oral administration in sheep. J. Vet. Pharmacol. Ther. 32, 359–367.

King, J., George, S., Garcia, R., Baker, K., Stein, P., Forster, S., Hosking, B., 2015. Zolvix® Plus Cattle – Efficacy against gastro-intestinal nematodes infecting cattle, in: 25º Conference
of the World Association for the Advancement of Veterinary Parasitology WAAVP.

Liverpool, United Kingdom, p. 263.

Lifschitz, A., Ballent, M., Virkel, G., Sallovitz, J., Viviani, P., Lanusse, C., 2014. Accumulation of monepantel and its sulphone derivative in tissues of nematode location in sheep: Pharmacokinetic support to its excellent nematodical activity. Vet. Parasitol. 203, 120–126.

MAFF (Ministry of Agriculture, Fisheries and Food), 1986. Manual of Veterinary Parasitological Laboratory Techniques. Her Majesty’s Stationery Office, London.

McKenna, P., 1990. The detection of anthelmintic resistance by the faecal egg count reduction test: An examination of some of the factors affecting performance and interpretation. N. Z. Vet. J. 38, 142–147.

Mederos, A., Serrano, C., Rinaldi, L., von Samson-Himmelstjerna, G., 2019. The Prevalence of Anthelmintic Resistance in Gastrointestinal Nematodes of Beef Cattle in Uruguay, in: 27° Conference of the World Association for the Advancements of Veterinary Parasitology (W.A.A.V.P.). Madison, Wisconsin, USA, pp. 274–275.

Mederos, A.E., Ramos, Z., Banchero, G., 2014. First report of monepantel Haemonchus contortus resistance on sheep farms in Uruguay. Parasites and Vectors 7, 1-4.

Perrier, D., Mayersohn, M., 1982. Non-compartmental determination of the steady-state volume of distribution for any mode of administration. J. Pharm. Sci. 71, 372–373.

Ramos, F., Portella, L., Rodrigues, F. de S., Reginato, C., Pötter, L., Cezar, A., Sangioni, L., Vogel, F., 2016. Anthelmintic resistance in gastrointestinal nematodes of beef cattle in the state of Rio Grande do Sul, Brazil. Int. J. Parasitol. Drugs Drug Resist. 6, 93–101.
Rendell, D.K., 2010. Anthelmintic resistance in cattle nematodes on 13 south-west Victorian properties. Aust. Vet. J. 88, 504–509.

Roberts, F., O’sullivan, P., 1950. Methods for egg counts and larval cultures for strongyles infesting the gastrointestinal tract of cattle. Crop Pasture Sci. 1, 99–102.

Rufener, L., Baur, R., Kaminsky, R., Mäser, P., Sigel, E., 2010. Monepantel allosterically activates DEG-3/DES-2 channels of the gastrointestinal nematode Haemonchus contortus. Mol. Pharmacol. 78, 895–902.

Rufener, L., Mäser, P., Roditi, I., Kaminsky, R., 2009. Haemonchus contortus acetylcholine receptors of the DEG-3 subfamily and their role in sensitivity to monepantel. PLoS Pathogens 5.

Sager, H., Hosking, B., Bapst, B., Stein, P., Vanhoff, K., Kaminsky, R., 2009. Efficacy of the amino-acetonitrile derivative, monepantel, against experimental and natural adult stage gastro-intestinal nematode infections in sheep. Vet. Parasitol. 159, 49–54.

Sales, N., Love, S., 2016. Resistance of Haemonchus sp. to monepantel and reduced efficacy of a derquantel/abamectin combination confirmed in sheep in NSW, Australia. Vet. Parasitol. 228, 193–196.

Sauermann, C., Leathwick, D., 2018. A climate-driven model for the dynamics of the free-living stages of Cooperia oncophora. Vet. Parasitol. 255, 83–90.

Scott, I., Pomroy, W.E., Kenyon, P.R., Smith, G., Adlington, B., Moss, A., 2013. Lack of efficacy of monepantel against Teladorsagia circumcincta and Trichostrongylus colubriformis. Vet. Parasitol. 198, 166–171.
Steffan P., Sánchez E., Entrocasso C., Fiel C., Lloberás M., Riva E., Guzmán M., 2011. Eficacia de Monepantel contra Nematodes de Ovinos con Resistencia Antihelmíntica Múltiple en la Región Templada de Argentina. Vet. Argentina 28, 1–12.

Turnbull, F., Devaney, E., Morrison, A.A., Laing, R., Bartley, D.J., 2019. Genotypic characterisation of monepantel resistance in historical and newly derived field strains of Teladorsagia circumcincta. Int. J. Parasitol. Drugs Drug Resist. 11, 59–69.

van den Brom, R., Moll, L., Kappert, C., Vellema, P., 2015. Haemonchus contortus resistance to monepantel in sheep. Vet. Parasit. 209, 278–280.

Waghorn, T., Leathwick, D., Rhodes, A., Jackson, R., Pomroy, W., West, D., Moffat, J., 2006. Prevalence of anthelmintic resistance on 62 beef cattle farms in the North Island of New Zealand. N. Z. Vet. J. 54, 278–282.

Figure Legends

**Figure 1**

Plasma concentration profiles of monepantel (MNP) and monepantel sulphone (MNPSO$_2$) obtained after the oral administration of monepantel (2.5 mg/kg) to parasitized calves (n=8). The insert shows the chemical structures of MNP and an its anthelmintically active metabolite MNPSO$_2$. 
Table 1

Plasma pharmacokinetic parameters (mean ± SD) for monepantel (MNP) and monepantel sulphone (MNPSO₂) obtained after the oral administration of MNP (2.5 mg/kg) to naturally parasitized calves.

| Pharmacokinetic parameters | MNP       | MNPSO₂    |
|----------------------------|-----------|-----------|
| Tₘₐₓ (h)                   | 8.00 ± 1.51<sup>a</sup> | 41.3 ± 17.9<sup>b</sup> |
| Cₘₐₓ (ng/mL)               | 21.5 ± 4.62<sup>a</sup> | 96.8 ± 29.7<sup>b</sup> |
| AUC₀-LOQ (ng.h/mL)         | 1709 ± 651<sup>a</sup> | 9220 ± 1720<sup>b</sup> |
| AUC₀-∞ (ng.h/mL)           | 2174 ± 783<sup>a</sup> | 10242 ± 1405<sup>b</sup> |
| MRT (h)                    | 112 ± 40.8<sup>a</sup> | 99.3 ± 21.0<sup>a</sup> |
| Tₜₜₑˡ (h)                  | 81.0 ± 31.0<sup>a</sup> | 57.6 ± 13.9<sup>a</sup> |
| Tₜₜ₃ₜₚₛₜₜₜₛₜₜₜₜₜₜₚₛₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜ৫° - Ratio of the AUC MNPSO₂/MNP

Tₘₐₓ: time to peak plasma concentration; Cₘₐₓ: peak plasma concentration; AUC₀-LOQ: area under the plasma concentration vs. time curve from 0 to the quantification limit; AUC₀-∞: area under the concentration-time curve extrapolated to infinity; MRT: mean residence time; Tₜₜₑˡ: elimination half-life; Tₜₜₚₛₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜₜ৫°: absorption half-life (the value express the metabolite formation half-life for MNPSO₂). Pharmacokinetic parameters with different superscript letters are statistically different (P<0.05).
Nematode egg per gram counts (EPG, arithmetic mean, range) and reduction percentages of faecal egg counts (FECR) (undifferentiated) with its 95% lower and upper confidence intervals, after the oral administration of monepantel (MNP, 2.5 mg/kg), and the subcutaneous administration of ivermectin (IVM, 0.2 mg/kg) and ricobendazole (RBZ, 3.75 mg/kg) to naturally parasitized calves.

Table 2

FECR estimated according to McKenna, (1990). CI: lower and upper confidence intervals.

| Experimental Group | EPG Counts (range) | FECR¹ (CI) | EPG Counts (range) | FECR¹ (CI) | EPG Counts (range) | FECR¹ (CI) |
|--------------------|--------------------|------------|--------------------|------------|--------------------|------------|
|                    | Day -1             | Day 15     |                    | Day -1     | Day 15             |            |
| MNP (oral)         | 547³ (100-2440)    | 5.6² (0-20)| 99% (97-99)        | 188³ (100-400) | 8³ (0-20)         | 96% (90-98) |
| IVM (sc)           | 469³ (100-1460)    | 269² (0-1060)| 43% (0-73)        | 351³ (100-660) | 111² (0-320)      | 68% (42-83) |
| RBZ (sc)           | 508³ (140-1380)    | 31³ (0-120)| 94% (85-97)       | 283³ (120-580) | 3³ (0-20)         | 98% (94-99) |
|                    |                    |            |                    |            |                    |            |
|                    | Day -1             | Day 15     |                    | Day -1     | Day 15             |            |
| MNP (oral)         | 188³ (100-400)     | 8³ (0-20)  | 96% (90-98)        | 374³ (140-740) | 7³ (0-20)         | 98% (95-99) |
| IVM (sc)           | 351³ (100-660)     | 111² (0-320)| 68% (42-83)       | 498³ (140-1360) | 362² (20-1520)    | 27% (0-69) |
| RBZ (sc)           | 283³ (120-580)     | 3³ (0-20)  | 98% (94-99)        | 480³ (140-1140) | 115² (0-320)      | 75% (45-89) |

¹FECR estimated according to McKenna, (1990). CI: lower and upper confidence intervals.
EPG counts on each column with different superscript letters are statistically different (P<0.05).
Table 3

Reduction percentages of faecal egg counts (FECR) for *Cooperia, Haemonchus, Ostertagia* and *Oesophagostomum* spp. after the oral administration of monepantel (MNP, 2.5 mg/kg), and the subcutaneous administration of ivermectin (IVM, 0.2 mg/kg) and ricobendazole (RBZ, 3.75 mg/kg) to naturally parasitized calves.

| Genus - Treatment | FECR<sup>1</sup> Day 15 |          |          |          |
|-------------------|-------------------------|----------|----------|----------|
|                   |                         | FARM 1   | FARM 2   | FARM 3   |
| *Cooperia* spp.   |                         |          |          |          |
| MNPoral           | 100%                    | 100%     | 100%     |
| IVMsc             | 80%                     | 56%      | 43%      |
| RBZsc             | 86%                     | 99%      | 54%      |
| *Haemonchus* spp. |                         |          |          |          |
| MNPoral           | 100%                    | 100%     | 100%     |
| IVMsc             | 19%                     | 100%     | 0%       |
| RBZsc             | 99%                     | 95%      | 98%      |
| *Ostertagia* spp. |                         |          |          |          |
| MNPoral           | 100%                    | 100%     | 99%      |
| IVMsc             | 100%                    | 100%     | 100%     |
| RBZsc             | 89%                     | 100%     | 0%       |
| *Oesophagostomum* spp. |                   | 74%      | 22%      | 64%      |
| MNPoral           | 100%                    | 100%     | 100%     |
| IVMsc             | 100%                    | 100%     | 100%     |
| RBZsc             | 100%                    | 100%     | 100%     |

<sup>1</sup>FECR estimated according to McKenna, (1990).
Figure 1

![Graph showing plasma concentration (ng/mL) over time (hours) for MNP and MNPSO₂. The graph includes error bars representing variability. The x-axis represents time in hours (0, 6, 12, 18, 24, 48, 72, 96, 120, 144, 168, 192, 216). The y-axis represents plasma concentration in ng/mL (0 to 120).]

Monepantel

Monepantel sulphone
HIGHLIGHTS

- MNP and its anthelmintically active metabolite MNPSO$_2$ were the main analytes recovered in plasma.
- The MNPSO$_2$ AUC value was 6-fold higher compared to the parent drug.
- MNP obtained overall efficacies of 96-99% against IVM and BZD resistant nematode parasites in cattle.
- MNP failed to control *Oesophagostomum* spp.
- The work described here reports for the first time an integrated assessment of MNP pharmaco-therapy features.
CONFLICT OF INTEREST STATEMENT

There are no potential conflicts of interest associated with this study.